MOREPENLAB2025-07-012025-09-30MOREPENLAB2025-09-30MOREPENLAB2025-03-31MOREPENLAB2025-04-012025-09-30MOREPENLAB2025-07-012025-09-30in-capmkt:OtherExpenses1MemberMOREPENLAB2025-07-012025-09-30in-capmkt:OtherExpenses2MemberMOREPENLAB2025-07-012025-09-30in-capmkt:OtherExpenses3MemberMOREPENLAB2025-07-012025-09-30in-capmkt:OtherExpenses4MemberMOREPENLAB2025-04-012025-09-30in-capmkt:OtherExpenses1MemberMOREPENLAB2025-04-012025-09-30in-capmkt:OtherExpenses2MemberMOREPENLAB2025-04-012025-09-30in-capmkt:OtherExpenses3MemberMOREPENLAB2025-04-012025-09-30in-capmkt:OtherExpenses4MemberMOREPENLAB2025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1MOREPENLAB2025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares500288MOREPENLABNOTLISTEDINE083A01026MOREPEN LABORATORIES LIMITEDMain BoardEquity2025-04-012026-03-312025-11-142025-11-07INRLakhsQuarterlySecond quarterSingle segmentPharmaceuticals2025-11-1411:30:002025-11-1415:00:00trueCash Flow IndirectNot applicable2025-07-012025-09-30UnauditedConsolidated41157580004636300041621210002206331000319818000115768000566525000418060001128080006003700003963426000198695000258254000456949000465140000465140000410435000000-1689000408746000-135210003952250000000109584100020.750.75000.750.751.'The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 14, 2025. A Limited review of the same has been carried out by the Statutory Auditors. <BR> <BR> 2'The Exceptional Items for the quarter comprise of - (i) the gain of Rs. 109.59 Lakhs arising from sale of equity shares at Rs. 20.03 per share in the subsidiary of the company, Dr. Morepen Limited (DML) on July 31, 2025 (ii) gain of Rs. 2472.95 Lakhs accounted for in accordance with 'Ind AS -110, Consolidated Financial Statements' on DML ceasing to be a subsidiary of the company.Since the company expects to realise its residual investments at amounts exceeding its present fair market value, no adjustment in carrying amount in accordance with 'IndAS-109 Financial Instuments' has been considered necessary as on date. <BR> <BR> 3.'The consolidated financial results for the quarter and half year ended 30th September, 2025 include the results of Dr. Morepen Limited (DML) as a subsidiary up to 31st July, 2025 and thereafter as an investment in equity instruments. <BR> <BR> 4.'The shareholders of the company approved final dividend of Rs. 0.20 per equity share of the face value of Rs. 2.00 each, in their Annual General meeting held on September 6, 2025, and dividend was paid on September 22, 2025. <BR> <BR> 5.'The Company is engaged in the Pharmaceutical Business Segment. <BR> <BR> 2025-04-012025-09-30UnauditedConsolidated8368146000904480008458594000458342000049021700019192700011188920008218400020305900014350360008104735000353859000258254000612113000876120000876120000524501000000-8272000516229000-76210005086080000000109584100020.950.95000.950.95Power and Fuel111690000Travelling Expenses55930000Selling and Distribution Expenses138638000Other Expenses294112000Power and Fuel217270000Travelling Expenses117821000Selling and Distribution Expenses442602000Other Expenses65734300034741750002554390000012380430000095116100000143200064789000662210000100645100069914900002721155000405955000273540500033189700070889000479600012411600036730580000397569100010369904000001736139400010958410001086649600011962337000712500011969462000198521000000894800002880010003899810006992300000747905000125385100016850002425709000242739400041044700040916920003584000001939350000046440270000053919320001736139400082184000172753000947300000-5592600000000-258254000-58854700002030590000-7385000000-2121000000000-827200000-3677790002443340000008572700001586070002783060000000000100000405727000371920000006499900000000000013919300000000000-5445840000000000067101000011800000562010001085780008218400003181500044406200058085000058085000273812000331897000Others-15290000-15290000Others-7385000-7385000-3890000-188500021210002121000-13521000-7621000